
EquitySector - HealthcareVery High Risk
Regular
NAV (20-Feb-26)
Returns (Since Inception)
Fund Size
₹545 Cr
Expense Ratio
2.33%
ISIN
INF251K01UY7
Minimum SIP
₹1,000
Exit Load
1.00%
Inception Date
27 Jun 2025
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
Since Inception
-5.83%
— (Cat Avg.)
| Equity | ₹527.81 Cr | 96.88% |
| Others | ₹17 Cr | 3.12% |
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹46.26 Cr | 8.49% |
| Mankind Pharma Ltd | Equity | ₹40.36 Cr | 7.41% |
| Cipla Ltd | Equity | ₹34.42 Cr | 6.32% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹31.57 Cr | 5.80% |
| Abbott India Ltd | Equity | ₹27.01 Cr | 4.96% |
| Lupin Ltd | Equity | ₹26.91 Cr | 4.94% |
| Torrent Pharmaceuticals Ltd | Equity | ₹25.75 Cr | 4.73% |
| Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹24.85 Cr | 4.56% |
| AstraZeneca Pharma India Ltd | Equity | ₹22.23 Cr | 4.08% |
| Ipca Laboratories Ltd | Equity | ₹21.48 Cr | 3.94% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹20.88 Cr | 3.83% |
| J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹18.7 Cr | 3.43% |
| ICICI Prudential Life Insurance Co Ltd | Equity | ₹18.47 Cr | 3.39% |
| Gland Pharma Ltd | Equity | ₹17.71 Cr | 3.25% |
| Fortis Healthcare Ltd | Equity | ₹17.03 Cr | 3.13% |
| Rainbow Childrens Medicare Ltd | Equity | ₹15.93 Cr | 2.92% |
| Laurus Labs Ltd | Equity | ₹15.44 Cr | 2.83% |
| Ajanta Pharma Ltd | Equity | ₹15.37 Cr | 2.82% |
| Emcure Pharmaceuticals Ltd | Equity | ₹14.64 Cr | 2.69% |
| Dr. Lal PathLabs Ltd | Equity | ₹14.1 Cr | 2.59% |
| Dr Reddy's Laboratories Ltd | Equity | ₹12.18 Cr | 2.24% |
| Clearing Corporation Of India Ltd | Cash - Repurchase Agreement | ₹11.48 Cr | 2.11% |
| Medplus Health Services Ltd | Equity | ₹10.39 Cr | 1.91% |
| Divi's Laboratories Ltd | Equity | ₹10.23 Cr | 1.88% |
| Inventurus Knowledge Solutions Ltd | Equity | ₹6.21 Cr | 1.14% |
| Jupiter Life Line Hospitals Ltd | Equity | ₹6.08 Cr | 1.12% |
| Net Receivables / (Payables) | Cash | ₹5.53 Cr | 1.01% |
| Metropolis Healthcare Ltd | Equity | ₹5.35 Cr | 0.98% |
| Nephrocare Health Services Ltd | Equity | ₹5.28 Cr | 0.97% |
| SBI Life Insurance Co Ltd | Equity | ₹3 Cr | 0.55% |
Large Cap Stocks
33.83%
Mid Cap Stocks
30.60%
Small Cap Stocks
32.45%
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹506.34 Cr | 92.94% |
| Financial Services | ₹21.47 Cr | 3.94% |
Standard Deviation
This fund
--
Cat. avg.
16.18%
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
0.91
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.60
Higher the better

Since June 2025
ISIN INF251K01UY7 | Expense Ratio 2.33% | Exit Load 1.00% | Fund Size ₹545 Cr | Age 7 months | Lumpsum Minimum ₹1,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Total AUM
₹51,861 Cr
Address
Crescenzo, 7th Floor, G-Block, Mumbai, 400 051
Your principal amount will be at Very High Risk

Download Dezerv App
Track and monitor all
your investments